Immunostimulant activities of a lipophilic muramyl dipeptide derivative and of desmuramyl peptidolipid analogs. 1980

M A Parant, and F M Audibert, and L A Chedid, and M R Level, and P L Lefrancier, and J P Choay, and E Lederer

The immunostimulant properties of a new muramyl dipeptide (MDP) derivative bearing a lipophilic moiety on the C-terminal end of the peptide chain are described. It is shown, in particular, that 1,O-(acetylmuramyl-L-alanyl-D-isoglutamine-L-alanyl)-glycerol-3-mycolate had increased immunostimulant activity in comparison with MDP. It induced hypersensitivity even when administered with an antigen in saline, and it gave higher protection against bacterial infections than did MDP. A quite unexpected finding was obtained with the corresponding desmuramyl compound 1,O-(L-alanyl-D-isoglutamine-L-alanyl)-glycerol-3-mycolate, which had no activity in producing humoral antibodies but was just as active as the muramic acid-containing compound in stimulating nonspecific resistance to bacterial infections. It was not pyrogenic. Modifications of the peptide moiety or the lipid moiety of this peptidolipid led to decrease, or even loss, of activity. These results show the importance of the N-acetylmuramyl moiety in MDP for humoral antibody production. The peptidolipid 1,O-(L-alanyl-D-isoglutamine-L-alanyl)-glycerol-3-mycolate is the first member of a new category of nonspecific immunostimulants.

UI MeSH Term Description Entries
D006968 Hypersensitivity, Delayed An increased reactivity to specific antigens mediated not by antibodies but by sensitized T CELLS. Hypersensitivity, Tuberculin-Type,Hypersensitivity, Type IV,Tuberculin-Type Hypersensitivity,Type IV Hypersensitivity,Delayed Hypersensitivity,Delayed Hypersensitivities,Hypersensitivity, Tuberculin Type,Tuberculin Type Hypersensitivity,Tuberculin-Type Hypersensitivities,Type IV Hypersensitivities
D007710 Klebsiella Infections Infections with bacteria of the genus KLEBSIELLA. Infections, Klebsiella,Infection, Klebsiella,Klebsiella Infection
D011008 Pneumococcal Infections Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE. Streptococcus pneumoniae Infections,Infections, Pneumococcal,Infections, Streptococcus pneumoniae,Pneumococcal Diseases,Disease, Pneumococcal,Diseases, Pneumococcal,Infection, Pneumococcal,Infection, Streptococcus pneumoniae,Pneumococcal Disease,Pneumococcal Infection,Streptococcus pneumoniae Infection
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D005334 Fever An abnormal elevation of body temperature, usually as a result of a pathologic process. Pyrexia,Fevers,Pyrexias
D006020 Glycopeptides Proteins which contain carbohydrate groups attached covalently to the polypeptide chain. The protein moiety is the predominant group with the carbohydrate making up only a small percentage of the total weight. Glycopeptide
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D000119 Acetylmuramyl-Alanyl-Isoglutamine Peptidoglycan immunoadjuvant originally isolated from bacterial cell wall fragments; also acts as pyrogen and may cause arthritis; stimulates both humoral and cellular immunity. Mur-NAc-L-Ala-D-isoGln,Muramyl Dipeptide,Acetylmuramyl Alanyl Isoglutamine,N-Acetyl-Muramyl-L-Alanyl-D-Glutamic-alpha-Amide,N-Acetylmuramyl-L-Alanyl-D-Isoglutamine,Alanyl Isoglutamine, Acetylmuramyl,Dipeptide, Muramyl,Isoglutamine, Acetylmuramyl Alanyl,Mur NAc L Ala D isoGln,N Acetyl Muramyl L Alanyl D Glutamic alpha Amide,N Acetylmuramyl L Alanyl D Isoglutamine
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

M A Parant, and F M Audibert, and L A Chedid, and M R Level, and P L Lefrancier, and J P Choay, and E Lederer
January 1992, Oncology research,
M A Parant, and F M Audibert, and L A Chedid, and M R Level, and P L Lefrancier, and J P Choay, and E Lederer
August 1980, Infection and immunity,
M A Parant, and F M Audibert, and L A Chedid, and M R Level, and P L Lefrancier, and J P Choay, and E Lederer
March 1995, Antiviral research,
M A Parant, and F M Audibert, and L A Chedid, and M R Level, and P L Lefrancier, and J P Choay, and E Lederer
January 1992, Postepy higieny i medycyny doswiadczalnej,
M A Parant, and F M Audibert, and L A Chedid, and M R Level, and P L Lefrancier, and J P Choay, and E Lederer
July 1993, International journal of immunopharmacology,
M A Parant, and F M Audibert, and L A Chedid, and M R Level, and P L Lefrancier, and J P Choay, and E Lederer
March 1984, Infection and immunity,
M A Parant, and F M Audibert, and L A Chedid, and M R Level, and P L Lefrancier, and J P Choay, and E Lederer
February 1989, Cancer research,
M A Parant, and F M Audibert, and L A Chedid, and M R Level, and P L Lefrancier, and J P Choay, and E Lederer
November 1989, Kekkaku : [Tuberculosis],
M A Parant, and F M Audibert, and L A Chedid, and M R Level, and P L Lefrancier, and J P Choay, and E Lederer
January 2016, ChemMedChem,
M A Parant, and F M Audibert, and L A Chedid, and M R Level, and P L Lefrancier, and J P Choay, and E Lederer
July 1988, Arzneimittel-Forschung,
Copied contents to your clipboard!